Antibodies and immunoblotting analyses. Affinity-purified rabbit polyclonal antibodies against human GEP100, human AMAP1, and human EPB41L5 were as described previously (21). These antibodies cross-reacted with each corresponding mouse antigen. Other antibodies were purchased from the commercial sources as listed in SI Appendix, Table S2 . Immunoblotting analysis was performed using the ECL kit (GE Healthcare), as described previously (17).
Plasmids. cDNAs encoding full-length human PDCD4, TEAD3, and ETV4 were amplified using PCR from first-strand cDNAs prepared from human fetal brain mRNAs (Clontech). These cDNAs were ligated into the NotI site of pCX4-bsr, in which a synthesized HA fragment was inserted into the BamHI/EcoRI site. All primers used for subcloning are listed in SI Appendix, Table S3 .
RNA interference and transfection. For transient siRNA-mediated gene silencing, cells were transfected with 50 nM each of the corresponding siRNA oligonucleotide duplexes (Japan BioService) using Lipofectamine RNAi Max (Invitrogen), according to the manufacturer's instructions. Two different sequences were used for each target, unless otherwise stated. Oligonucleotide duplexes with an irrelevant sequence were from Dharmacon. All target sequences for siRNA are listed in SI Appendix, Table S4 .
For stable shRNA-mediated gene silencing, we used pLKO.1-puro-based recombinant lentiviruses either generated by ourselves or purchased from Addgene. In brief, shRNAs were constructed in pLKO.1-puro from the Sigma Mission shRNA library as listed in SI Appendix, Table S5 . A control scramble shRNA in pLKO.1-puro (1864, Addgene) were transfected into 293FT cells, together with the envelope plasmid pMD2.G (12259, Addgene) and the packaging plasmid psPAX2 (12260, Addgene), using Lipofectamine LTX (Invitrogen) according to the manufacturer's instructions. Forty-eight hours after the transfection, culture supernatants were harvested, filtered through 0.45-µm filters (Advantec), and the resultant lentivirus preparations were then applied onto target cells in the presence of Polybrene (8 µg mL -1 ). After 24 hours, 4 µg mL -1 puromycin was added to the culture for one week to select infected cells. All target sequences for shRNAs are listed in SI Appendix, Table S5 .
ARF6 activity measurements. ARF6 activities were measured using the GST-GGA-pulldown method, as described previously (25 These processes were all performed at room temperature.
Evaluation of IHC staining. At least two microarray tissue cores of each clinical sample were subjected to IHC and results were evaluated by two clinical doctors independently using light microscopes with a magnification of × 200. Staining intensities were graded on a scale from 0 to 2 (0, no staining; 1, weak staining; and 2, strong staining); and percentages of the stained areas were calculated as proportions (0 if 0%, 0.1-0.9 if 10%-90%, respectively, and 1 if 100%). Proportional scores were then multiplied by the staining grades to obtain H scores. The final H score of each sample was indicated as an average H score of each corresponding core. For p53 staining, strong p53 immunostaining in > 5% of neoplastic cells was classified as p53-high, and < 5% was as p53-low. The overall survival of patients was defined as the interval between surgery and death, or between surgery and the last observation point. For surviving patients, data were censored at the last follow up. Disease-free survival was defined as the interval between the date of surgery and the date of diagnosis of any type of relapse. Differences in survival between groups were analyzed by the log-rank test.
All statistical analyses were performed with EZR (Saitama Medical Center, Jichi
Medical University, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 2.13.0).
Sucrose gradient centrifugation to determine polysome profiles. MIAPaCa-2 cells transfected with siRNA were lysed in polysome buffer (20 mM HEPES-KOH [pH 7.5], 100 mM KCl, 5 mM MgCl 2 , 0.25% (vol/vol) Nonidet P-40, 100 µg/mL cycloheximide, 100 units/mL RNase inhibitor, and protease inhibitor cocktail). Lysates were loaded on top of a linear 15%-60% sucrose gradient (15%-60% sucrose, 20 mM HEPES-KOH [pH 7.5], 100 mM KCl, 5 mM MgCl 2 , 10 µg/mL cycloheximide, 100 units/mL RNase inhibitor, and protease inhibitor cocktail). After ultracentrifugation at 38,000 rpm for 2.5 hours at 4 ºC in a HITACHI P40ST rotor, fractions were collected from the top of the gradient and subjected to UV-densitometric analysis. The absorbance profiles of the gradients were determined at 254 nm. For RNA analysis, each fraction was subjected to High Pure RNA Isolation Kit (Roche) and RT-PCR.
In vitro translation and in vitro transcription. In vitro transcription of mRNAs in the presence of either 7 mGpppG (Gcap) or ApppG (Acap) and micrococcal nuclease treatment were performed as described previously (61, 62). Briefly, 10 µL of micrococcal nuclease-treated MIAPaCa-2 cell extracts, 12.5 µL of reaction buffer (62) and 2.5 µL of 50 nM reporter mRNAs were incubated at 37 ºC for 60 min. The reaction was stopped by liquid N 2 , and the luciferase reporter assay was performed according to the manufacturer's protocol (NanoGlo Luciferase Assay Systems, Promega).
RNA-seq analysis. Total RNAs were extracted using RNeasy Mini kit (Qiagen) Dual-luciferase reporter assays. Human PDCD4 promoter reporter constructs, #1-#6, were generated using PCR amplification and subcloned into the EcoRV site of pGL4.20 Immunofluorescence microscopy. Immunofluorescence microscopy analysis was performed according to the method described previously (22). Briefly, MIAPaCa-2 cells were transfected by siRNAs or infected with shRNA lentiviruses and incubated for 24
hours, or incubated with 1 µM Simvastatin or DMSO for 24 hours. Cells were then incubated with IFNγ (50 ng mL -1 ) for another 48 hours before fixation with 4% paraformaldehyde in PBS (no detergent was added). Cells were then subjected to immunostaining using an anti-PD-L1 antibody, followed by an Alexa Fluor 555-conjugated secondary antibody. F-actin was visualized using Alexa Fluor 488-conjugated phalloidin, and nuclei were stained with DAPI before mounting with 50% glycerol in PBS. Fluorescence images were obtained with a confocal laser-scanning microscope (Model A1R with NIS-Elements, Nikon) using a CFI Plan Apo VC 60 × H oil-immersion objective with an NA of 1.4, and analyzed with the attached software. Data were collected from two independent experiments, each analyzing at least 10 cells. Images were handled using Photoshop version 7 (Adobe). Recycling assay. Recycling of PD-L1 to the plasma membrane was measured by an antibody labeling-based method, similar to that performed previously with β1 integrin (22). In brief, cells were first incubated with an anti-PD-L1 antibody (1 µg mL -1 ; clone 27A2, MBL) in DMEM on ice for 30 min. After washing twice with ice-cold PBS, cells were incubated with culture media with 2% FCS at 37 °C for 2 hours , followed by washing once with an acidic buffer (0.5% glacial acetic acid (pH 3.0), 0.5 M NaCl) for 2 min to remove antibodies remaining on the cell surface. Cells were then washed twice with ice-cold PBS, fixed in 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in PBS at room temperature for 10 min, to measure the amounts of internalized PD-L1. For the recycling assay, following the acid wash, cells were incubated with culture media containing 2% FCS with or without PDGF (50 ng mL -1 ) at 37 °C in a CO 2 incubator for the indicated times, and then fixed without permeabilization. Each cell preparation was then incubated with an IR dye 800-conjugated anti-mouse IgG antibody
(1:800, LI-COR) to label the anti-PD-L1 antibodies, and DRAQ5 (1:20,000, Biostatus), a cell-permeable nuclear staining dye, at room temperature for 1 hour. Staining intensities were then measured with the Odyssey Infrared Imaging System (LI-COR) using 700 and 800 nm channels. Control nonimmune mouse IgGs were used to measure the nonspecific background, and these values were subtracted from each measurement.
Data were collected from two independent experiments, each performed in duplicate. Table S3 .
Reverse transcription-polymerase chain reaction (RT-PCR

Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Total
RNAs were extracted from the cells using RNeasy Mini kit (Qiagen), according to the manufacturer's instructions. RNAs (15 ng each) were then reverse-transcribed using the patients with different GEP100 expression levels (High, score of 1 or 2; Low, score 0).
P-values were calculated by the log-rank test. 
